Many patients with IBD report persisting symptoms, despite resolution of the inflammatory process. Although by definition, a ...

In the wake of the presidential election, another change in interest rates and continued news about geopolitical unrest, the appeal of blue-chip stocks is stronger than ever. That' ...

To help you in your search, three Fool.com contributors have pulled together reports on a few opportunities they think are ...

However, arguably the next best thing is for a company to belong to the elite group known as Dividend Kings. To qualify, a ...

You can be a little greedy sometimes and find great stocks that possess solid growth prospects and also pay dividends.

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

"Year to date" sales for 2021, 2022, 2023, and 2024 sales are shown in series at the top of the table and then just below a comparison of 2024 versus 2023 and 2024 versus 2022 is displayed. This ...

NORTH CHICAGO, Ill. and BRANFORD, Conn., Oct. 31, 2024 (GLOBE NEWSWIRE) -- AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics ...

The neurological biomarkers market is expanding as neurological disorders, including dementia and Parkinson's disease, become more prevalent with an aging global population. Innovations in biomarker ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.

LATEST NEWS 07:15 Live News: Asian markets update; Fianna Fáil, Fine Gael and Sinn Féin’s housing plans rated 05:00 Comer brothers told to change plans for apartments next to Maynooth church 05:00 ...